Page 21234..1020..»

Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021

By Dr. Matthew Watson

TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its first quarter 2021 financial results after the market closes on Thursday May 6, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The rest is here:
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021

To Read More: Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
categoriaGlobal News Feed commentoComments Off on Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021 | dataApril 19th, 2021
Read All

Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,…

By Dr. Matthew Watson

EMERYVILLE, Calif., April 16, 2021 (GLOBE NEWSWIRE) --  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA® (fenfluramine) on patients with Dravet syndrome, a rare, severe epilepsy, and on their caregivers and families. Data from the study is being presented during the virtual American Academy of Neurology (AAN) Annual Meeting, April 17-22, 2021.

See original here:
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,...

To Read More: Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,…
categoriaGlobal News Feed commentoComments Off on Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,… | dataApril 19th, 2021
Read All

Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 

By Dr. Matthew Watson

-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in wet age-related macular degeneration (wet AMD) during the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Meeting. Preclinical data on ADVM-062, a novel IVT gene therapy that also utilizes Adverum’s proprietary vector capsid AAV.7m8, in blue cone monochromacy will also be presented.

Read the original here:
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 

To Read More: Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 
categoriaGlobal News Feed commentoComments Off on Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021  | dataApril 19th, 2021
Read All

LIDDS Annual Report 2020

By Dr. Matthew Watson

UPPSALA, SWEDEN – LIDDS publishes Annual Report for 2020

Link:
LIDDS Annual Report 2020

To Read More: LIDDS Annual Report 2020
categoriaGlobal News Feed commentoComments Off on LIDDS Annual Report 2020 | dataApril 19th, 2021
Read All

Vistin Pharma ASA: Invitation to Q1 2021 conference call

By Dr. Matthew Watson

Oslo, Norway, 16 April 2021

See original here:
Vistin Pharma ASA: Invitation to Q1 2021 conference call

To Read More: Vistin Pharma ASA: Invitation to Q1 2021 conference call
categoriaGlobal News Feed commentoComments Off on Vistin Pharma ASA: Invitation to Q1 2021 conference call | dataApril 19th, 2021
Read All

Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

By Dr. Matthew Watson

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day at 1:00 p.m. ET on Thursday, April 22, 2021.

Originally posted here:
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

To Read More: Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
categoriaGlobal News Feed commentoComments Off on Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 | dataApril 19th, 2021
Read All

Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020

By Dr. Matthew Watson

CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020.

Continued here:
Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020

To Read More: Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020
categoriaGlobal News Feed commentoComments Off on Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020 | dataApril 19th, 2021
Read All

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking…

By Dr. Matthew Watson

BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from the US Phase 3 open-label long-term (12-month) safety study of sofpironium bromide gel, 5% and 15% were selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology’s (AAD) 2021 Virtual Meeting Experience (VMX) being held April 23– 25, 2021. Also, as one of the top twelve late-breaking research abstracts, Brickell has been invited to participate in a live Q&A session on April 24th from 2:00 PM – 3:00 PM CT.

Read this article:
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking...

To Read More: Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking…
categoriaGlobal News Feed commentoComments Off on Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking… | dataApril 19th, 2021
Read All

Sanofi completes Kiadis acquisition

By Dr. Matthew Watson

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

Continued here:
Sanofi completes Kiadis acquisition

To Read More: Sanofi completes Kiadis acquisition
categoriaGlobal News Feed commentoComments Off on Sanofi completes Kiadis acquisition | dataApril 19th, 2021
Read All

Virbac : Declaration of the number of shares and voting rights March 2021

By Dr. Matthew Watson

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

See the rest here:
Virbac : Declaration of the number of shares and voting rights March 2021

To Read More: Virbac : Declaration of the number of shares and voting rights March 2021
categoriaGlobal News Feed commentoComments Off on Virbac : Declaration of the number of shares and voting rights March 2021 | dataApril 19th, 2021
Read All

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

By Dr. Matthew Watson

SAN JOSE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology (CDA) technology, or paid CDA-based tests, in the first quarter of 2021, setting a record high Q1 test volume. CDA-based tests, which are multi-cancer tests based on a novel biophysical approach, are the Company’s flagship product line and reached 5,439 paid cancer tests in Q1, an approximately 130% increase over the same period last year. While AnPac Bio offers multiple test products including various cancer screening tests, immunology tests and annual physical checkups, paid CDA-based tests had the highest test volume among all these tests in Q1, 2021.

See more here:
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

To Read More: AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
categoriaGlobal News Feed commentoComments Off on AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 | dataApril 19th, 2021
Read All

Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

By Dr. Matthew Watson

WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstracts were accepted for presentation at the virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 1-7, 2021. These abstracts feature a breadth of data, from presentations that demonstrate the potential of AI to analyze the growth of GA lesions, to new safety and efficacy data for pegcetacoplan, an investigational targeted C3 therapy, in GA.

Here is the original post:
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

To Read More: Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
categoriaGlobal News Feed commentoComments Off on Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | dataApril 19th, 2021
Read All

Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021

By Dr. Matthew Watson

TORONTO, April 16, 2021 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, is pleased to announce that it has received final approval from the Toronto Stock Exchange (“TSX”) to graduate from the TSX Venture Exchange (“TSXV”) and list its common shares on the TSX.

Read more:
Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021

To Read More: Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021
categoriaGlobal News Feed commentoComments Off on Auxly Receives Approval to Begin Trading on the Toronto Stock Exchange April 20, 2021 | dataApril 19th, 2021
Read All

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies…

By Dr. Matthew Watson

COPENHAGEN, Denmark, April 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

Read the rest here:
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies...

To Read More: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies…
categoriaGlobal News Feed commentoComments Off on Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies… | dataApril 19th, 2021
Read All

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology…

By Dr. Matthew Watson

DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the presentation of positive secondary endpoint data at the 2021 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 17-22, 2021. FT218 is currently under review at the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) target date of October 15, 2021.

See the article here:
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology...

To Read More: Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology…
categoriaGlobal News Feed commentoComments Off on Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology… | dataApril 19th, 2021
Read All

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking…

By Dr. Matthew Watson

Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy

Read the original:
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking...

To Read More: VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking…
categoriaGlobal News Feed commentoComments Off on VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking… | dataApril 19th, 2021
Read All

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021

By Dr. Matthew Watson

MARSEILLE, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at April 1, 2021:

See the original post here:
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021

To Read More: Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021
categoriaGlobal News Feed commentoComments Off on Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021 | dataApril 19th, 2021
Read All

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

By Dr. Matthew Watson

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

Read more here:
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

To Read More: European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
categoriaGlobal News Feed commentoComments Off on European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma | dataApril 19th, 2021
Read All

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

By Dr. Matthew Watson

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Originally posted here:
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

To Read More: ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
categoriaGlobal News Feed commentoComments Off on ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer | dataApril 19th, 2021
Read All

Nicox Provides First Quarter 2021 Business Update and Financial Highlights

By Dr. Matthew Watson

See the article here:
Nicox Provides First Quarter 2021 Business Update and Financial Highlights

To Read More: Nicox Provides First Quarter 2021 Business Update and Financial Highlights
categoriaGlobal News Feed commentoComments Off on Nicox Provides First Quarter 2021 Business Update and Financial Highlights | dataApril 19th, 2021
Read All

Page 21234..1020..»